(PHVS) Pharvaris BV - Overview
Stock: Deucrictibant, Oral Capsule, Oral Tablet, Prophylaxis, Treatment
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 71.9% |
| Relative Tail Risk | -9.04% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.81 |
| Alpha | 39.78 |
| Character TTM | |
|---|---|
| Beta | 0.592 |
| Beta Downside | 0.379 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.11% |
| CAGR/Max DD | 0.65 |
Description: PHVS Pharvaris BV January 14, 2026
Pharvaris N.V. (NASDAQ:PHVS) is a late-stage biotech focused on rare, bradykinin-mediated diseases, principally hereditary and acquired angioedema. Its lead asset, deucrictibant, is a small-molecule B2-receptor antagonist being tested in Phase 3 for both acute treatment and prophylaxis of HAE attacks, with both an extended-release tablet and an immediate-release capsule under development. The company, incorporated in 2015 and based in Zug, Switzerland, targets a market estimated at $2-3 billion globally for angioedema therapies.
Key recent metrics (as of Q4 2025) include a cash runway of roughly $78 million, sufficient to fund ongoing Phase 3 trials and a planned U.S. regulatory filing in early 2026. The trial’s primary endpoint-reduction in time to symptom resolution-met statistical significance, positioning deucrictibant against established biologics such as lanadelumab and berinert, while offering a potentially lower-cost oral alternative. The broader biotech sector continues to benefit from strong R&D tax incentives in Europe and sustained investor appetite for rare-disease pipelines, which historically command premium valuations due to limited competition and high unmet need.
For a deeper, data-driven valuation, see the ValueRay profile on PHVS.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.40 > 0.02 and ΔFCF/TA -4.73 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.40 > 3% & CFO -134.1m > Net Income -163.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.3m) vs 12m ago 15.14% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -2.84 > 6 (EBITDA TTM -119.6m / Interest Expense TTM 42.3m) |
Altman Z'' -15.00
| A: 0.92 (Total Current Assets 337.2m - Total Current Liabilities 26.2m) / Total Assets 338.9m |
| B: -1.57 (Retained Earnings -532.4m / Total Assets 338.9m) |
| C: -0.37 (EBIT TTM -119.9m / Avg Total Assets 326.0m) |
| D: -17.91 (Book Value of Equity -477.3m / Total Liabilities 26.7m) |
| Altman-Z'' Score: -20.37 = D |
What is the price of PHVS shares?
Over the past week, the price has changed by -2.33%, over one month by +9.85%, over three months by +21.19% and over the past year by +44.69%.
Is PHVS a buy, sell or hold?
- StrongBuy: 6
- Buy: 2
- Hold: 0
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the PHVS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 46.8 | 77.1% |
| Analysts Target Price | 46.8 | 77.1% |
| ValueRay Target Price | 30.5 | 15.5% |
PHVS Fundamental Data Overview February 03, 2026
P/B = 4.6988
Revenue TTM = 0.0 EUR
EBIT TTM = -119.9m EUR
EBITDA TTM = -119.6m EUR
Long Term Debt = 578.7k EUR (from capitalLeaseObligations, last quarter)
Short Term Debt = 137.6k EUR (from shortTermDebt, last quarter)
Debt = 578.7k EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -328.7m EUR (from netDebt column, last quarter)
Enterprise Value = 1.16b EUR (1.49b + Debt 578.7k - CCE 329.3m)
Interest Coverage Ratio = -2.84 (Ebit TTM -119.9m / Interest Expense TTM 42.3m)
EV/FCF = -8.63x (Enterprise Value 1.16b / FCF TTM -134.4m)
FCF Yield = -11.59% (FCF TTM -134.4m / Enterprise Value 1.16b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 97.0k) / Revenue TTM)
Tobins Q-Ratio = 3.42 (Enterprise Value 1.16b / Total Assets 338.9m)
Interest Expense / Debt = 1.58% (Interest Expense 9135 / Debt 578.7k)
Taxrate = 21.0% (US default 21%)
NOPAT = -94.7m (EBIT -119.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.86 (Total Current Assets 337.2m / Total Current Liabilities 26.2m)
Debt / Equity = 0.00 (Debt 578.7k / totalStockholderEquity, last quarter 312.2m)
Debt / EBITDA = 2.75 (negative EBITDA) (Net Debt -328.7m / EBITDA -119.6m)
Debt / FCF = 2.45 (negative FCF - burning cash) (Net Debt -328.7m / FCF TTM -134.4m)
Total Stockholder Equity = 247.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -50.22% (Net Income -163.7m / Total Assets 338.9m)
RoE = -66.17% (Net Income TTM -163.7m / Total Stockholder Equity 247.4m)
RoCE = -48.34% (EBIT -119.9m / Capital Employed (Equity 247.4m + L.T.Debt 578.7k))
RoIC = -38.28% (negative operating profit) (NOPAT -94.7m / Invested Capital 247.4m)
WACC = 8.10% (E(1.49b)/V(1.49b) * Re(8.10%) + D(578.7k)/V(1.49b) * Rd(1.58%) * (1-Tc(0.21)))
Discount Rate = 8.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.11%
Fair Price DCF = unknown (Cash Flow -134.4m)
EPS Correlation: -35.00 | EPS CAGR: -13.42% | SUE: 0.63 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.64 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=6
EPS next Year (2026-12-31): EPS=-2.74 | Chg30d=+0.000 | Revisions Net=+4 | Growth EPS=+0.6% | Growth Revenue=+0.0%